Camp4 Therapeutics CORP 8-K Filing

Ticker: CAMP · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1736730

Sentiment: neutral

Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-07 16:16:11

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. From time to time, Camp4 Therapeutics Corporation (the "Company") intends to conduct meetings with third parties in which its current corporate slide presentation is presented. A copy of this slide presentation, dated January 2025, is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On January 7, 2025, the Company issued a press release reporting safety data from all four cohorts of the single ascending dose, or SAD, portion of its ongoing Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers and highlighting certain other recent corporate updates and key upcoming milestones. The full text of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Slide presentation, dated January 2025. 99.2 Press release, dated January 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CAMP4 THERAPEUTICS CORPORATION By: /s/ Josh Mandel-Brehm Name: Josh Mandel-Brehm Title: President and Chief Executive Officer Date: January 7, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing